[Pyr¹]-Apelin-13 (Human, Bovine)

4361-v 0.5 mg | 70.00 EUR

Pyr-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe

Synthetic Product

The purity is guaranteed to be higher than 99% by HPLC

Ligand for APJ Receptor

Apelin has been described as endogenous ligand for human APJ. Its pyroglutaminated C-terminal peptide [Pyr¹]-Apelin-13 ( [pGlu]-Apelin-13 ) was more potent than Apelin-36 in competitive inhibition assays. This pyroglutaminated peptide shows in vivo very high vascular effects. [Pyr¹]-Apelin-13 shows a clear vasodilation effect in man.

References:

1. K. Tatemoto, M. Hosoya, Y. Habata, R. Fujii, T. Takegawa, M.-X. Zou, Y. Kawamata, S. Fukusumi, S. Hinuma, C. Kitada, T. Kurokawa, H. Onda and M. Fujino, Biochem. Biophys. Res. Commun., 251, 471 (1998) (Original; Human and Bovine)
2. M.X. Zou, H.Y. Liu, Y. Haraguchi, Y. Soda, K. Tatemoto and H. Hoshido, FEBS Lett., 473, 15 (2000) (Pharmacol.)
3. M. Hosoya, Y. Kawamata, S. Fukusumi, R. Fujii, Y. Habata, S. Hinuma, C. Kitada, S. Honda, T. Kurukawa, H. Onda, O. Nishimura and M. Fujino, J. Biol. Chem., 275, 21061 (2000) (Pharmacol.)

The synthetic peptide [Pyr1]-Apelin-13 is distributed through Peptide Institute, Inc. under the license of Takeda Pharmaceutical Company , Ltd.